![]() Multivalent vaccines are routinely used in Europe and elsewhere against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B (HB), and invasive diseases caused Haemophilus influenzae type b (Hib). Thus, Hexyon ® is a convenient, useful option for vaccination against childhood diseases caused by six major pathogens. ![]() However, Hexyon ® offers the convenience of full-liquid, ready-to-use formulation, which may minimize vaccination errors and preparation time. The immunogenicity and safety profile of Hexyon ® was similar to that of several approved vaccines, including Infanrix hexa™. Hexyon ® has a good reactogenicity/safety profile. ![]() Coadministration of Hexyon ® with other common childhood vaccines did not affect immune response to any vaccines. Hexyon ® can be used for a mixed primary series of hexavalent-pentavalent-hexavalent vaccines or as a booster in infants primed with Infanrix hexa™ or pentavalent (whole-cell or acellular pertussis) vaccines. It provides durable protection against hepatitis B. Hexyon ® is highly immunogenic for all its component toxoids/antigens when used as primary and booster vaccine in infants and toddlers, irrespective of vaccination schedule. While the source of HB antigen in Hexyon ® is different from other vaccines, the rest of its valences have been extensively used in other approved vaccines. Hexyon ® is a fully-liquid, ready-to-use, hexavalent vaccine approved in the EU since 2013 for primary and booster vaccination in infants and toddlers from age 6 weeks against diphtheria, tetanus, pertussis, hepatitis B (HB), poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b (Hib).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |